HS-276

• Description:

  HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Casein Kinase; IRAK; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/hs-276.html

• Purity:

  98.93

• Solubility:

  DMSO : 50 mg/mL (ultrasonic; warming; adjust pH to 2 with 1M HCl; heat to 60°C)

• Smiles:

  O=C(C1=CC=CC(C(NC2=NC3=C(N2CCC)C=C(CN4CCCCC4)C=C3)=O)=C1)N

• Molecular Formula:

  C24H29N5O2

• Molecular Weight:

  419.52

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Scarneo S, et al. Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis. ACS Chem Biol. 2022 Mar 18;17 (3) :536-544.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  IRAK1; IRAK4

• CAS Number:

  [2767422-72-8]